GMAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Genmab A/S (GMAB) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has positive long-term catalysts in 2026 and a generally favorable analyst rating, the recent financial performance, lack of significant news, and neutral trading sentiment suggest waiting for a better entry point. The SwingMax signal indicates a short-term opportunity, but it is not aligned with the user's long-term investment strategy.
The MACD histogram is negative (-0.0845) and contracting, indicating bearish momentum. RSI is at 32.039, which is neutral but close to oversold territory. Moving averages are converging, suggesting indecision in price movement. Key support is at 28.349, and resistance is at 30.909. The stock is trading near its pivot level of 29.629.
Analysts highlight a 'catalyst-rich' 2026 with potential sales growth opportunities. Recent acquisitions mitigate terminal value risk. Analysts maintain generally favorable ratings with price targets ranging from $34 to $48.
The company's Q4 2025 financials showed a significant decline in net income (-94.38% YoY) and EPS (-94.26% YoY). Gross margin also dropped slightly (-2.59% YoY). Technical indicators suggest bearish momentum. No significant news or trading trends from hedge funds, insiders, or Congress.
In Q4 2025, revenue increased by 14.63% YoY to $1.058 billion. However, net income dropped significantly by 94.38% YoY to $31 million, and EPS fell by 94.26% YoY to $0.49. Gross margin declined slightly to 92.34%.
Analysts generally maintain a Buy rating with price targets ranging from $34 to $48. Recent updates reflect optimism for 2026 catalysts but acknowledge near-term challenges, such as lowered estimates for Epkinly and the failure of the EPCORE DLBCL-1 trial.
